In which patients is vasopressin most likely to be used?

In which patients is vasopressin most likely to be used?

• A. Patients on ACE inhibitors or ARBs with catecholamine-resistant hypotension
• B. Hypotension responsive to catecholamines
• C. High cardiac output states
• D. Tachycardia-prone patients

Answer: (A)

Vasopressin is used as an adjunct vasopressor in vasodilatory shock when catecholamines alone fail to restore blood pressure. It works through V1 receptors to cause vasoconstriction, and its effect is independent of the adrenergic pathways that catecholamines use. This makes it especially helpful when the body's own vasopressin stores are depleted or when other systems are already blocked. In patients who are on ACE inhibitors or ARBs, the renin-angiotensin system’s ability to contribute to vasoconstriction is diminished. That reduces the effectiveness of catecholamines alone. Adding vasopressin provides a different mechanism to raise vascular tone and can help restore blood pressure when hypotension is resistant to catecholamines. So, this scenario—patients on ACE inhibitors or ARBs with catecholamine-resistant hypotension—is where vasopressin is most likely to be used. It is less beneficial if the patient’s hypotension is already responding to catecholamines, and it’s not typically the main choice for high-output states or for tachycardia-prone patients unless the clinical context supports vasopressin use.

Vasopressin is used as an adjunct vasopressor in vasodilatory shock when catecholamines alone fail to restore blood pressure. It works through V1 receptors to cause vasoconstriction, and its effect is independent of the adrenergic pathways that catecholamines use. This makes it especially helpful when the body's own vasopressin stores are depleted or when other systems are already blocked.

In patients who are on ACE inhibitors or ARBs, the renin-angiotensin system’s ability to contribute to vasoconstriction is diminished. That reduces the effectiveness of catecholamines alone. Adding vasopressin provides a different mechanism to raise vascular tone and can help restore blood pressure when hypotension is resistant to catecholamines.

So, this scenario—patients on ACE inhibitors or ARBs with catecholamine-resistant hypotension—is where vasopressin is most likely to be used. It is less beneficial if the patient’s hypotension is already responding to catecholamines, and it’s not typically the main choice for high-output states or for tachycardia-prone patients unless the clinical context supports vasopressin use.